LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2)Erwei Song, Fan Feng, Jiuda Zhao et al.|Annals of Oncology|2025Cited by 2